Biotech operations. Keep the evidence as the program changes.

Biotech startup software should preserve the evidence behind a program as work moves from discovery into regulated development. It should connect experiments, materials, samples, process and analytical definitions, quality decisions, external partners, and CMC evidence without forcing every activity into GMP controls before those controls are warranted.

Seal configures those activities on one operating model. A scientist can follow why a process parameter was chosen. Quality can see which version entered controlled use. A sponsor can trace a CDMO batch back to the approved process and forward to the evidence used for disposition.

An emerging biotech rarely needs every enterprise system on its first day. It needs the controls appropriate to the work it performs now and a deliberate path for the records that will matter later.

The software architecture should follow those operating needs. Buying an ELN, QMS, LIMS, MES, and data warehouse independently can digitize each department while leaving the product history to be reconstructed between them.

The program is the organizing spine: therapeutic candidate, modality, target product profile, development stage, intended markets, product and process definitions, analytical strategy, suppliers, partners, risks, commitments, and evidence.

Experiments, samples, methods, batches, deviations, and documents remain distinct records, but each resolves to the program and the version of the product or process it informed. Teams can ask which evidence supports a decision without searching five repositories or treating a folder name as provenance.

The ICH Q10 pharmaceutical quality system model spans pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation, with knowledge management and quality risk management across the lifecycle. Seal makes that continuity operational at the record level.

Discovery work and regulated work should be connected, not governed identically. An early experiment may need authorship, timestamps, source data, materials, and reproducibility without an approved protocol or quality-unit signature. A method used for a release decision needs a controlled version, qualified users and instruments, approved calculations, review, and change control.

Seal assigns controls from intended use, lifecycle state, record type, risk, and applicable procedure. Promotion into controlled use is an explicit transition with review, effective version, training or qualification impact, validation evidence, and retained development history.

Part 11 is not a blanket platform label. The FDA's Part 11 guidance ties electronic-record controls to predicate-rule records and recommends a justified, documented, risk-based approach to validation. Seal supplies access control, audit history, signatures, versioning, and validation evidence; the customer defines intended use and validates the configured process in its operating context.

An experiment records hypothesis, protocol or method, materials, equipment, conditions, observations, raw-data references, calculations, results, author, review where required, and conclusion. Structured entities can sit beside narrative work, so flexibility does not require losing identity or provenance.

A conclusion becomes a knowledge claim only when its source evidence, scope, limitations, author, review state, and affected product or process are explicit. Conflicting results remain visible. Supersession does not erase the earlier interpretation.

That distinction matters at transfer. “Run at pH 7.0” is an instruction. The experiments, model, ranges, and rationale behind it are process knowledge. Seal retains both.

Cell lines, plasmids, constructs, antibodies, standards, reagents, media, excipients, reference materials, and critical consumables retain identity, source, lot or lineage, preparation, storage, status, expiry, and use.

Samples inherit program, experiment or batch, source material, collection point, container, quantity, condition, custody, storage location, derivatives, tests, results, and disposition. Parent-child genealogy survives aliquoting, pooling, shipment, consumption, and destruction.

If a reagent lot, freezer excursion, assay issue, or sample discrepancy later matters, the affected work is a query rather than a retrospective spreadsheet exercise.

Development runs connect unit operations, materials, equipment, scale, parameters, samples, results, yields, quality attributes, exceptions, and conclusions. Comparisons across runs preserve the actual configuration used rather than flattening it into a presentation.

As the process matures, approved knowledge becomes a versioned process definition with inputs, sequence, parameters, ranges, calculations, hold times, sampling, acceptance rules, and allowed branches. Scale-up, characterization, engineering, clinical, PPQ, and commercial contexts can share the definition while retaining their different purpose and evidence requirements.

Technology transfer then starts from the controlled definition and its evidence. Site adaptations, equipment fit, material differences, analytical readiness, risks, gaps, actions, training, qualification, and engineering evidence remain connected to the receiving process version. Transfer does not become a fresh document that paraphrases the source process.

Analytical target profiles, method experiments, parameters, standards, preparations, instrument data, calculations, forced degradation, robustness, validation, transfer, and routine performance form one method history.

The exploratory method remains distinct from the effective QC method. Promotion identifies what changed, what evidence supports the controlled version, what must be validated or transferred, and which specifications and samples use it.

Where a chromatography data system, scientific data platform, or specialist analysis application remains authoritative, Seal retains the source reference, acquisition context, transformation, review, and reported result. It does not make a copied value the original record.

Quality should become more formal as product knowledge, patient exposure, organizational complexity, and regulatory commitments increase. The FDA guidance for Phase 1 investigational drugs describes quality-control principles appropriate to early clinical manufacture rather than a single undifferentiated burden.

Seal can introduce controlled documents, training, suppliers, deviations, CAPA, change control, risk, audits, validation, and management review in the sequence the operating model requires. The underlying relationships already exist, so adding control does not require abandoning the research and development history.

A deviation in a clinical batch can open with the executed step, process version, material lots, equipment, samples, results, and prior development evidence attached. A change can identify affected methods, documents, training, partners, submissions, and future batches before approval.

A virtual biotech may rely on CROs, testing laboratories, consultants, logistics providers, and CDMOs. Each partner can keep its authoritative systems while the sponsor retains the agreed operating view.

Quality agreements define responsibilities, records, decision rights, notifications, clocks, and escalation. Transfers use controlled manifests rather than email attachment lists. Receipt, completeness, questions, acceptance, and supersession are separate states.

The sponsor can follow process transfer, material readiness, batch milestones, deviations, test results, release evidence, changes, and commitments at the level its role requires. Portal access or integration does not silently transfer approval authority between organizations.

Product and process descriptions, control strategy, material controls, manufacturing history, analytical methods, specifications, validation, stability, comparability, and change assessments draw from governed source records.

Seal can assemble a reviewable evidence set and draft source-bound narrative from those records. Each statement retains its sources and applicable versions. Regulatory authors decide what belongs in a submission, reconcile differences, and approve the final text.

When a health-authority question or internal review challenges a claim, the team can move from narrative to the experiments, batches, results, decisions, and changes behind it. The value is not automatic submission writing. It is avoiding unsupported prose and last-minute reconstruction.

neil can extract entities and parameters from protocols, suggest schemas, map imported records, compare versions, identify missing evidence, and draft workflows or narratives. Every proposal retains its source, confidence, and unresolved conflicts.

Scientists, process owners, quality, and regulatory reviewers approve changes within their authority. AI does not establish a specification, accept a deviation, determine GMP applicability, release a batch, or approve a filing.

This boundary makes AI output useful to both people and downstream agents: a proposed fact is visibly different from an approved fact, and every material statement can be traced to its evidence.

Seal can operate ELN, inventory, sample management, process development, QMS, LIMS, electronic batch records, tech transfer, and controlled partner workflows on one platform. A biotech can adopt only the parts it needs and add controls without changing the underlying program identity.

Seal does not need to replace every specialist application. Bioinformatics pipelines, molecular modeling, image analysis, chromatography data systems, ERP, clinical EDC, safety systems, and regulatory publishing tools may remain authoritative for their domains. Seal connects their relevant records, states, evidence, and decisions to the program.

The goal is not one database for everything. It is one accountable path from scientific evidence to the work and decisions that depend on it.

The first implementation should follow one real candidate through a meaningful transition: an experiment to a process decision, a method into controlled use, a sample through external testing, a process into CDMO transfer, or a clinical batch through review.

Include the failure paths: conflicting evidence, an expired material, a changed method, missing partner data, a deviation, a late result, and a superseded process version. The system is ready when the team can answer what changed, why, who approved it, which work used it, and what evidence supports the current state—without reconstructing the answer from folders and email.